Antidepressant-3-halophenylpiperazinyl-propyl derivatives of substituted triazolones and triazoldiones
CA 2094890 C · Owner: Bristol-Myers Squibb Company · Inventors: Luke, George M.; Mayol, Robert F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
2-(3-4-(3-Halophenyl)-1-piperazinylpropyl derivatives of certain 4-alkyl-or 4-phenoxyalkyl-2,4-dihydro-3H-1,2,4triazol-3-ones and triazol-3,5-diones are psychotropic agents having promise as antidepressants by virtue of their receptor site binding affinity profiles and animal pharmacology. Compounds of Formula I and their acid addition salts and/or hydrates are disclosed: (see formula I), In the foregoing structural formula the symbol R denotes halogen, preferably chloro, or trifluoromethyl; Z is hydrogen or, (see formula II), with R1 being hydrogen halogen, C1-4 alkoxy and, trifluoromethyl; and n is an integer from 2-4. The symbol X is either an oxygen atom, providing a carbonyl moiety; or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 26, 1993 and granted April 11, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 26, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 26, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.